EMEA-003045-PIP01-21
Key facts
| Active substance |
Rusfertide
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0422/2021
|
| PIP number |
EMEA-003045-PIP01-21
|
| Pharmaceutical form(s) |
Powder and solvent for solution for injection
|
| Condition(s) / indication(s) |
Treatment of polycythaemia vera
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Protagonist Therapeutics, Inc.
Email: ptgxclintrials@ptgx-inc.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|